January 1, New Test Could Spare Men From Needless Prostate Cancer Treatment

Wyatt’s Take

• A simple molecular test now helps doctors decide which men with high-risk prostate cancer actually need strong hormone therapy and which can safely skip it.
• Researchers found that men with low test scores face lower odds of the cancer spreading, so they can avoid the fatigue and other harsh side effects that come with extra drugs.
• One in eight American men will face prostate cancer, and this tool gives families and doctors a clearer path to protect both life and quality of life.

A new diagnostic tool is giving doctors better information about which men with aggressive prostate cancer need tougher treatment and which men can safely avoid it.

The test, called Decipher, looks at the molecular makeup of prostate tumors to predict how likely the cancer is to spread.

Researchers at University College London studied results from more than 27,000 patients plus 401 men who took part in the big STAMPEDE trial on abiraterone, a hormone therapy that cuts death risk in half for high-risk cases.

“Understanding who benefits most from additional treatment can make a meaningful difference,” said Dr. Sarah Howlett of the UCL Cancer Institute.

Men with high Decipher scores were more likely to see their cancer spread, so they stood to gain the most from stronger therapy.

Men with low scores showed less risk of spread, meaning they could skip the extra drugs and the side effects that come with them.

“Prostate cancer varies from person to person,” said Fox News senior medical analyst Dr. Marc Siegel. “Medical science is increasingly aware that it is not one size fits all.”

Siegel said hormone therapies can bring on serious fatigue and do not always help every patient.

The study combined real-world data with a randomized trial, strengthening the evidence that the test can guide treatment choices before side effects set in.

“We believe this growing evidence gives physicians a stronger reason to use Decipher before making decisions that can affect both cancer outcomes and patients’ quality of life,” said Elai Davicioni of Veracyte, the company that makes the test.

Prostate cancer remains the second-leading cause of cancer death among American men, behind only lung cancer.

Localized prostate cancer still holds hidden clues in its DNA that can show whether the disease will stay quiet or turn deadly.

“But further validation in other datasets is needed before the test is used routinely to make these decisions,” Howlett cautioned.

The study shows that knowing those clues early can spare men unnecessary drugs while making sure the right patients get the full treatment they need.

Wyatt Matters

Middle America families want straight answers and practical tools that protect their loved ones without turning every diagnosis into a lifetime of harsh side effects. This kind of clear science keeps decisions in the hands of patients and doctors, not distant regulators or insurance clerks.